# Data Sheet (Cat.No.T27630)

TargetMol

## Isbogrel

### Chemical Properties




CAS No. : 89667-40-3

Formula: C18H19NO2

Molecular Weight: 281.35

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

### Biological Description

| | |
|---|---|
| Description | Isbogrel (CV4151) is a small molecule thromboxane A2 synthase (TXA2 synthase) inhibitor that can be used to study cardiac arrhythmias, transient ischemic attacks and thrombosis. |
| Targets(IC50) | Prostaglandin Receptor |
| In vivo | Isbogrel significantly inhibited photochemically induced MCA thrombosis by oral (1 and 10 mg/kg) and intravenous (1 mg/kg) administration.[2]<br>Isbogrel (10 mg/kg, p.o.), furthermore, significantly reduced the infarct size and inhibited the increase in lactate content. Isbogrel might be a useful drug for the treatment of cerebral thrombosis and for the prevention of cerebral infarction.[2] |

### Solubility Information

| | |
|---|---|
| Solubility | DMSO: 55 mg/mL (195.49 mM),Sonication is recommended.<br>(< 1 mg/ml refers to the product slightly soluble or insoluble) |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|---|---|---|---|
| 1 mM | 3.5543 mL | 17.7715 mL | 35.5429 mL |
| 5 mM | 0.7109 mL | 3.5543 mL | 7.1086 mL |
| 10 mM | 0.3554 mL | 1.7771 mL | 3.5543 mL |
| 50 mM | 0.0711 mL | 0.3554 mL | 0.7109 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Terashita Z, et al. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. J Lipid Mediat Cell Signal. 1996 Jan;13(1):1-8.
Imura Y, et al. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995 Jul 1;79(1):95-107.
Asai F, et al. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Arzneimittelforschung. 1991 May;41(5):506-10.
Terashita Z, et al. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res. 1995 Mar 1;77(5):411-21.